80 / 89
80
breakthrough and acid reflux in patients with
systemic sclerosis - a randomized controlled,
cross-over trial. Aliment Pharmacol Ther
2007;26:1259-65.
90.
Shoenut JP, Wieler JA, Micflikier AB. The extent
and pattern of gastro-oesophageal reflux in
patients with scleroderma oesophagus: the
effect of low-dose omeprazole. Aliment
Pharmacol Ther 1993;7:509-13.
91.
Pakozdi A, Wilson H, Black CM, Denton CP.
Does long term therapy with lansoprazole slow
progression of oesophageal involvement in
systemic sclerosis? Clin Exp Rheumatol
2009;27(3 Suppl 54):5-8.
92.
Wipff J, Coriat R, Masciocchi M, Caramaschi P,
Derk CT, Hachulla E, et al. Outcomes of
Barrett's oesophagus related to systemic
sclerosis: a 3-year EULAR Scleroderma Trials
and Research prospective follow-up study.
Rheumatology (Oxford) 2011;50:1440-4.
93.
Kent MS, Luketich JD, Irshad K, Awais O,
Alvelo-Rivera M, Churilla P, et al. Comparison
of
surgical
approaches
to
recalcitrant
gastroesophageal reflux disease in the patient
with
scleroderma.
Ann
Thorac
Surg
2007;84:1710-5.
94.
Lundberg AC, Akesson A, Akesson B. Dietary
intake and nutritional status in patients with
systemic
sclerosis.
Ann
Rheum
Dis
1992;51:1143-8.